ArticleThe Biochemical journal2003
Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression.
Article in The Biochemical journal, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 62 citations in OpenAlex.
- Review
- Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes.International journal of molecular sciences · 2023Article
- Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers.Journal of advanced research · 2023Article
- HER2-Low Breast Cancer: Current Landscape and Future Prospects.Breast cancer (Dove Medical Press) · 2023Review
- Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance.EBioMedicine · 2020Article
- Germline and SomaticCancer prevention research (Philadelphia, Pa.) · 2018Article
- Article
- The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.Journal of mammary gland biology and neoplasia · 2014Review
- Uncovering enhancer functions using the α-globin locus.PLoS genetics · 2014Review
- Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies.Oncogene · 2014Article
- Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer.Neoplasia (New York, N.Y.) · 2012Article
- Alternative TFAP2A isoforms have distinct activities in breast cancer.Breast cancer research : BCR · 2011Article
- Identification of target genes of transcription factor activator protein 2 gamma in breast cancer cells.BMC cancer · 2009Article
- Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification.Breast cancer research : BCR · 2009Article
- Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines.Breast cancer research : BCR · 2009Article
- AP-2 factors act in concert with Notch to orchestrate terminal differentiation in skin epidermis.The Journal of cell biology · 2008Article
- Induction of ErbB2 by ultraviolet A irradiation: potential role in malignant transformation of keratinocytes.Cancer science · 2008Article
- The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors.Breast cancer research : BCR · 2008Article
- HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.European journal of immunology · 2007Article
- AP-2alpha: a regulator of EGF receptor signaling and proliferation in skin epidermis.The Journal of cell biology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ERBB2 gene is overexpressed in 30% of human breast cancers and this is correlated with poor prognosis. Overexpression of the ERBB2 gene is due to increased transcription and gene amplification. Our previous studies have identified a new cis element in the ERBB2 promoter which is involved in the gene's overexpression. This cis element, located 501 bp upstream from the main ERBB2 transcription initiation site, binds a transcription factor called HTF (HER2 transcription factor). We report here the identification of HTF as an AP-2 (activator protein-2) transcription factor. The new cis element is bound by AP-2 with high affinity, compared with a previously described AP-2 binding site located 284 bp downstream. Co-transfection of an AP-2alpha expression vector with a reporter vector containing the newly identified AP-2 binding site in front of a minimal ERBB2 promoter induced a dose-dependent increase in transcriptional activity. We examined the contribution of the new AP-2 binding site to ERBB2 overexpression. For this purpose we abolished the new and/or the previously described AP-2 binding sequence by site-directed mutagenesis. The results show that the two functional AP-2 sites in the first 700 bp of the ERBB2 promoter co-operate to achieve maximal transcriptional activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.